195 related articles for article (PubMed ID: 14722234)
1. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
[TBL] [Abstract][Full Text] [Related]
2. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
Harikumar KG; Miller LJ
J Biol Chem; 2005 May; 280(19):18631-5. PubMed ID: 15757907
[TBL] [Abstract][Full Text] [Related]
4. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
[TBL] [Abstract][Full Text] [Related]
5. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
Hadac EM; Ji Z; Pinon DI; Henne RM; Lybrand TP; Miller LJ
J Med Chem; 1999 Jun; 42(12):2105-11. PubMed ID: 10377216
[TBL] [Abstract][Full Text] [Related]
6. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
Dong M; Liu G; Pinon DI; Miller LJ
Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
Dong M; Lam PC; Pinon DI; Abagyan R; Miller LJ
Biochemistry; 2009 Jun; 48(23):5303-12. PubMed ID: 19441839
[TBL] [Abstract][Full Text] [Related]
8. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
Anders J; Blüggel M; Meyer HE; Kühne R; ter Laak AM; Kojro E; Fahrenholz F
Biochemistry; 1999 May; 38(19):6043-55. PubMed ID: 10320330
[TBL] [Abstract][Full Text] [Related]
9. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
[TBL] [Abstract][Full Text] [Related]
10. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
11. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
Foucaud M; Archer-Lahlou E; Marco E; Tikhonova IG; Maigret B; Escrieut C; Langer I; Fourmy D
Regul Pept; 2008 Jan; 145(1-3):17-23. PubMed ID: 17961734
[TBL] [Abstract][Full Text] [Related]
12. Conformational and molecular modeling studies of sulfated cholecystokinin-15.
Giragossian C; Stone S; Papini AM; Moroder L; Mierke DF
Biochem Biophys Res Commun; 2002 May; 293(3):1053-9. PubMed ID: 12051766
[TBL] [Abstract][Full Text] [Related]
13. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling.
Lutz J; Romano-Götsch R; Escrieut C; Fourmy D; Mathä B; Müller G; Kessler H; Moroder L
Biopolymers; 1997 Jun; 41(7):799-817. PubMed ID: 9128441
[TBL] [Abstract][Full Text] [Related]
14. Single amino acid substitution of serine82 to asparagine in first intracellular loop of human cholecystokinin (CCK)-B receptor confers full cyclic AMP responses to CCK and gastrin.
Wu SV; Yang M; Avedian D; Birnbaumer M; Walsh JH
Mol Pharmacol; 1999 May; 55(5):795-803. PubMed ID: 10220557
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.
Harikumar KG; Pinon DI; Miller LJ
Biosci Rep; 2006 Apr; 26(2):89-100. PubMed ID: 16779661
[TBL] [Abstract][Full Text] [Related]
16. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.
Harikumar KG; Gao F; Pinon DI; Miller LJ
Biochemistry; 2008 Sep; 47(36):9574-81. PubMed ID: 18700727
[TBL] [Abstract][Full Text] [Related]
17. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor.
Ghanekar D; Hadac EM; Holicky EL; Miller LJ
J Pharmacol Exp Ther; 1997 Sep; 282(3):1206-12. PubMed ID: 9316827
[TBL] [Abstract][Full Text] [Related]
18. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
Schmitz F; Pratt DS; Wu MJ; Kolakowski LF; Beinborn M; Kopin AS
Mol Pharmacol; 1996 Aug; 50(2):436-41. PubMed ID: 8700154
[TBL] [Abstract][Full Text] [Related]
19. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.
Dong M; Hadac EM; Pinon DI; Miller LJ
Mol Pharmacol; 2005 Jun; 67(6):1892-900. PubMed ID: 15774770
[TBL] [Abstract][Full Text] [Related]
20. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
